ZI H04
Alternative Names: ZI-H04Latest Information Update: 28 Jan 2024
At a glance
- Originator Zelluna Immunotherapy
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Solid-tumours in Norway (Parenteral)
- 05 Feb 2021 ZI H04 is available for licensing as of 24 Sep 2020. https://www.zelluna.com/partnering
- 28 Sep 2020 Zelluna Immunotherapy plans a phase I/II trial in Solid tumours (Second-line therapy or greater) in Norway in 2020 (Zelluna Immunotherapy pipeline, December 2019)